Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 3:45 PM
Ignite Modification Date:
2025-12-25 @ 1:52 PM
NCT ID:
NCT01953692
Pre Assignment Details:
Participants were enrolled in disease-specific cohorts (C): C1: myelodysplastic syndrome (MDS); C2: multiple myeloma (MM); C3: Hodgkin lymphoma (HL); C4: non-Hodgkin lymphoma consisting of:
* 4A: primary mediastinal B-cell lymphoma (PMBCL)
* 4B: Non-PMBCL + programmed cell death ligand 1 positive. DLBCL and FL were included in 4C and 4D. The remaining diseases in 4B were classified as "Other"
* 4C: follicular lymphoma (FL)
* 4D: diffuse large B-cell lymphoma (DLBCL) And C5: DLBCL
Recruitment Details:
The study included an initial dose determination for Cohort 5 to determine the recommended Phase 2 dose (RP2D) of lenalidomide. Participants started at a dose of 25 mg. The RP2D dose was set at 20 mg and subsequent participants were enrolled at that dose.
Study:
NCT01953692
Study Brief:
Results Section:
NCT01953692